新型冠状病毒治疗药物中和抗体临床应用进展
Progress in clinical application of neutralizing antibodies against SARS-CoV-2
王璐 1曾露 1桂玲 1魏安华1
作者信息
- 1. 华中科技大学同济医学院附属同济医院药学部,武汉 430030
- 折叠
摘要
新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)在全球范围内持续流行,严重威胁人类生命健康,开发有效治疗药物尤为重要.中和抗体作为一种特异性抗病毒治疗药物,药品研发和临床应用都取得较快进展,目前已有部分中和抗体获得紧急使用授权,应用于COVID-19 患者的治疗.因此本文对中和抗体类新型冠状病毒治疗药物的临床应用及有效性、安全性进行综述,以期为临床用药提供参考.
Abstract
The ongoing global epidemic of COVID-19 has exerted a serious impact on life quality of human.Therefore,the development of effective therapeutic agents is particularly important.As specific antiviral agents,neutralizing antibodies have been successfully applied on some viral infectious diseases.Currently,the development of neutralizing antibodies against SARS-CoV-2 is progressing rapidly,and several products have been authorized for emergency use.In this paper,the clinical application,efficacy and safety of SARS-CoV-2 neutralizing antibodies are reviewed,in order to provide reference for the clinical application of neutralizing antibodies.
关键词
新型冠状病毒/中和抗体/有效性/安全性/临床应用进展Key words
SARS-CoV-2/neutralizing antibody/efficacy/safety/clinical application progress引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据